Acrivon Advances ACR-7280, an Optimized, AP3-Enabled, Potential First-in-Class, Oral CDK11 Inhibitor Toward IND Filing in First Half of 2027
Stocks in this Quantisnow insightHealth Care
Quantisnow market dataNASDAQ
ACRV
Acrivon Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2022
Get push alerts for ACRV
Full ACRV profile on Quantisnow Follow ACRV and get a push notification the moment its next story breaks.